J&J calls its jab 'valuable' protection against virus strains

Friday, 23. April 2021 21:30

Johnson and Johnson (J&J) stressed on Friday that its vaccine against COVID-19 is "valuable" to both the United States and the world and that it protects from different variants of the virus.

Dr. Mathai Mammen, global head of Janssen Research and Development, added the major advantage of the company's jab in comparison to those produced by Pfizer Inc. and BionTech SE, and Moderna Inc. is that it is easy to store and distribute.

J&J's comments come in the midst of the Centres for Disease Control and Prevention's (CDC) review and voting on whether the company's vaccine should be used or not. Its rollout was temporarily halted over suspicions it leads to the creation of blood clots.

Related Links: Johnson & Johnson
Breaking the News / JR